Publications by authors named "Mitsuhiro Rokuda"

Claim this Profile
C
Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda

Diabetes Obes Metab· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda

J Diabetes Investig· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda

J Diabetes Investig· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Mitsuhiro Rokuda

Mod Rheumatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis.
Norio Abiru, Shingo Shoji, Yoshinori Kosakai, Robert Snijder, Keiko Asakawa, Mitsuhiro Rokuda

Diabetes Res Clin Pract· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Mitsuhiro Rokuda

Mod Rheumatol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Yoshiya Tanaka, Tsutomu Takeuchi, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato, Mitsuhiro Rokuda

Arthritis Res Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, Hiroyuki Izutsu, Yuichiro Kaneko

Mod Rheumatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Mitsuhiro Rokuda

Rheumatol Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Mitsuhiro Rokuda

Arthritis Res Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Mitsuhiro Rokuda

Arthritis Res Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Mitsuhiro Rokuda

Ann Rheum Dis· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Mitsuhiro Rokuda

Ann Rheum Dis· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
Mitsuhiro Rokuda, Naoki Matsumaru, Katsura Tsukamoto

Clin Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of VopT, a novel ADP-ribosyltransferase effector protein secreted via the Vibrio parahaemolyticus type III secretion system 2.
Toshio Kodama, Mitsuhiro Rokuda, Kwon-Sam Park, Vlademir V Cantarelli, Shigeaki Matsuda

Cell Microbiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional characterization of two type III secretion systems of Vibrio parahaemolyticus.
Kwon-Sam Park, Takahiro Ono, Mitsuhiro Rokuda, Myoung-Ho Jang, Kazuhisa Okada

Infect Immun· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxicity and enterotoxicity of the thermostable direct hemolysin-deletion mutants of Vibrio parahaemolyticus.
Kwon-Sam Park, Takahiro Ono, Mitsuhiro Rokuda, Myoung-Ho Jang, Tetsuya Iida

Microbiol Immunol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis